Adial Pharmaceuticals
ADIL
22 hedge funds and large institutions have $778K invested in Adial Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 1 closing their positions.
10,660% more capital inflows, than outflows
Capital inflows: $958K | Capital outflows: $8.9K
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
38% more funds holding
Funds holding: 16 → 22 (+6)
10.48% more ownership
Funds ownership: 2.8% → 13.28% (+10%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$827K |
| 2 |
Jane Street
New York
|
+$35.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$24.6K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$21.4K |
| 5 |
Virtu Financial
New York
|
+$20.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$3.1K |
| 2 |
HRT Financial
New York
|
-$3K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$2.71K |
| 4 |
SBI Securities
Tokyo,
Japan
|
-$81 |
| 5 |
Tower Research Capital (TRC)
New York
|
-$8 |
ADIL Hedge Fund Activity: Q4 2025 in Review
22 of the 8,294 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q4 2025, worth a combined $778K — up 262% from $215K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ADIL positions and 1 closed out — a net gain of 6 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $827K. The largest seller was UBS Group, cutting an estimated $3.1K.
- 22 institutional investors held Adial Pharmaceuticals (ADIL) as of Q4 2025, up from 16 in Q3 2025.
- Funds reported $778K of Adial Pharmaceuticals stock for Q4 2025, up 262% quarter-over-quarter.
- 7 funds opened new Adial Pharmaceuticals positions in Q4 2025 and 1 closed out, a net change of +6 holders.
- The largest Adial Pharmaceuticals buyer in Q4 2025 was Armistice Capital, an estimated $827K added.
- The largest Adial Pharmaceuticals seller in Q4 2025 was UBS Group, an estimated $3.1K sold.
Based on aggregated 13F filings for Q4 2025.